Adagio Medical Appoints Bolsters C-Suite to Accelerate Commercial Readiness

Adagio Medical Holdings Inc. has augmented its senior leadership team by hiring Marie-Claude Jacques as senior vice president, Global Sales, and Antwan Gipson as senior vice president, Manufacturing and Operations.

“These appointments represent a significant milestone as Adagio prepares for commercialization of our proprietary Ultra-Low Temperature Cardiac Ablation technology (ULTC) for electrophysiology (EP),” Adagio Medical CEO Todd Usen said. “Marie-Claude is a proven commercial leader with a track record at Baylis of introducing a disruptive technology and energy source as a small entrant into the established EP market and growing these into widely adopted tools for EP, which culminated in the acquisition of Baylis by Boston Scientific. Antwan brings over two decades of leadership experience building scalable, compliant manufacturing infrastructures for energy-based and catheter-based devices in high-growth organizations. Their complementary skills will be instrumental as we prepare for the commercial launch of our ULTC ablation platform.”

Jacques has more than 15 years of commercial leadership experience in electrophysiology and interventional cardiology with deep expertise in global market development, sales force build-out, and physician adoption of novel technologies. She most recently served as chief commercial officer at Catheter Precision, where she led global sales and marketing for the commercial launches of VIVO, a non-invasive 3D mapping system, and LockeT, a venous closure device. Previously, Jacques was vice president of Sales and Marketing at Baylis Medical, where she built and led a 100-person organization and helped scale the company’s electrophysiology and transseptal access portfolio to double-digit growth and more than $170 million in annual revenue. She spent two years as a sales vice president at Boston Scientific after the Baylis acquisition.

Jacques earned an MBA from Warwick Business School (UK), graduate certificates in business law (USC Gould School of Law) and business communication (Harvard Extension School), and recently completed the MIT Sloan Executive Program in Artificial Intelligence in Healthcare.

“It is an honor to be a member of this team at Adagio and to be a part of the future of ULTC,” Jacques stated. “I am excited to help build a global commercial organization that will partner with electrophysiologists to redefine outcomes in complex arrhythmia patients with this new tool.”

Gipson has more than 20 years of experience leading manufacturing, quality, supply chain, and logistics across high-growth medical technology companies. Most recently, he served as vice president of Operations and Quality Sciences at Decobolus Consultancy Group. Prior to that, he held senior leadership roles at Candesant Biomedical, Nano Precision Medical, and Tautona Group.

Gipson has a proven track record of scaling manufacturing from proof-of-concept through commercial launch, increasing production capacity by 10 to 100-fold in compressed timelines to support commercial launches, reducing cost of goods by up to 75%, and building audit-ready quality systems that have supported successful regulatory clearances. He earned a doctorate in business from CIU Irvine, an MBA specializing in operations analytics and technology from Angelo State University, and a bachelor of science degree in engineering and technology from Northern Michigan University.

“Adagio’s technology platform presents a rare opportunity to combine precision engineering with transformative patient impact,” Gipson said. “I look forward to building a scalable, cost-efficient, and high-quality manufacturing infrastructure that not only supports efficient global supply, but enables attractive gross margins and long-term commercial sustainability.”

“The addition of Marie-Claude and Antwan underscores our focus on execution, scale, and disciplined commercialization,” Usen added. “Their combined leadership will be central to achieving our commercialization goals in 2026 and beyond and to creating lasting value for our patients, customers and shareholders.”

Adagio is a medical device company developing and commercializing products to treat cardiac arrhythmias using its proprietary, catheter-based Ultra-Low Temperature Cardiac (ULTC) ablation technology. ULTC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The company is currently focused on treating ventricular arrhythmias with its purpose-built vCLAS Cryoablation System, which is CE Marked and is currently under evaluation in the FULCRUM-VT U.S. Pivotal IDE Trial.

FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia) is a prospective, multi-center, open-label, single-arm trial that has fully enrolled 209 patients with structural heart disease of both ischemic and non-ischemic cardiomyopathy, indicated for catheter ablation of drug refractory VT in accordance with current treatment guidelines. The results of the study will be used to apply for U.S. Food and Drug Administration premarket approval (PMA) for Adagio’s vCLAS Cryoablation System, potentially leading to the broadest industry indication for purely endocardial ablation of scar-mediated VT.

Adagio’s vCLAS Cryoablation System is commercially available to treat monomorphic VT in Europe and select other geographies but is limited to investigational use in the United States.